486 related articles for article (PubMed ID: 31548347)
1. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M
Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347
[TBL] [Abstract][Full Text] [Related]
2. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Pathological Characteristics of
Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
[No Abstract] [Full Text] [Related]
4. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
5. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
[TBL] [Abstract][Full Text] [Related]
6. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS
Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821
[TBL] [Abstract][Full Text] [Related]
7. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
[TBL] [Abstract][Full Text] [Related]
9. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
Arolt C; Dugan M; Wild R; Richartz V; Holz B; Scheel AH; Brägelmann J; Wagener-Ryczek S; Merkelbach-Bruse S; Wolf J; Buettner R; Catanzariti L; Scheffler M; Hillmer AM
J Thorac Oncol; 2023 Nov; 18(11):1550-1567. PubMed ID: 37473958
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
[TBL] [Abstract][Full Text] [Related]
11. Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.
Hellyer JA; Padda SK; Diehn M; Wakelee HA
J Thorac Oncol; 2021 Mar; 16(3):395-403. PubMed ID: 33307193
[TBL] [Abstract][Full Text] [Related]
12. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
[TBL] [Abstract][Full Text] [Related]
13.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
14. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
[TBL] [Abstract][Full Text] [Related]
15. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
16. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
17. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
Paik PK; Fan PD; Qeriqi B; Namakydoust A; Daly B; Ahn L; Kim R; Plodkowski A; Ni A; Chang J; Fanaroff R; Ladanyi M; de Stanchina E; Rudin CM
J Thorac Oncol; 2023 Apr; 18(4):516-526. PubMed ID: 36240971
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
19. KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis".
Mazzotta M; Marinelli D; Maugeri-Saccà M
J Thorac Oncol; 2020 Jun; 15(6):e87-e88. PubMed ID: 32471566
[No Abstract] [Full Text] [Related]
20. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR
Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]